A rationale for continuing mass antibiotic distributions for trachoma

Kathryn J Ray, Travis C Porco, Kevin C Hong, David C Lee, Wondu Alemayehu, Muluken Melese, Takele Lakew, Elizabeth Yi, Jenafir House, Jaya D Chidambaram, John P Whitcher, Bruce D Gaynor, Thomas M Lietman, Kathryn J Ray, Travis C Porco, Kevin C Hong, David C Lee, Wondu Alemayehu, Muluken Melese, Takele Lakew, Elizabeth Yi, Jenafir House, Jaya D Chidambaram, John P Whitcher, Bruce D Gaynor, Thomas M Lietman

Abstract

Background: The World Health Organization recommends periodic mass antibiotic distributions to reduce the ocular strains of chlamydia that cause trachoma, the world's leading cause of infectious blindness. Their stated goal is to control infection, not to completely eliminate it. A single mass distribution can dramatically reduce the prevalence of infection. However, if infection is not eliminated in every individual in the community, it may gradually return back into the community, so often repeated treatments are necessary. Since public health groups are reluctant to distribute antibiotics indefinitely, we are still in need of a proven long-term rationale. Here we use mathematical models to demonstrate that repeated antibiotic distributions can eliminate infection in a reasonable time period.

Methods: We fit parameters of a stochastic epidemiological transmission model to data collected before and 6 months after a mass antibiotic distribution in a region of Ethiopia that is one of the most severely affected areas in the world. We validate the model by comparing our predicted results to Ethiopian data which was collected biannually for two years past the initial mass antibiotic distribution. We use the model to simulate the effect of different treatment programs in terms of local elimination of infection.

Results: Simulations show that the average prevalence of infection across all villages progressively decreases after each treatment, as long as the frequency and coverage of antibiotics are high enough. Infection can be eliminated in more villages with each round of treatment. However, in the communities where infection is not eliminated, it returns to the same average level, forming the same stationary distribution. This phenomenon is also seen in subsequent epidemiological data from Ethiopia. Simulations suggest that a biannual treatment plan implemented for 5 years will lead to elimination in 95% of all villages.

Conclusion: Local elimination from a community is theoretically possible, even in the most severely infected communities. However, elimination from larger areas may require repeated biannual treatments and prevention of re-introduction from outside to treated areas.

Figures

Figure 1
Figure 1
a. Deterministic Model of Time vs. Prevalence with biannual treatments: Results from a differential equation based model demonstrating that biannual coverage of 80% of the population should progressively reduce ocular chlamydial infection (blue curve). The deterministic model is an excellent approximation for the expectation of the stochastic model (mean of 1000 simulations, red curve). b. Stochastic Model of Time vs. Prevalence with biannual treatments: The mean of 1000 simulations of a stochastic model, assuming biannual treatments with 80% coverage (again, red curve) vs. the average prevalence of only those villages which still harbor infection (green curve). After the third treatment, the average prevalence of infection in these villages returns to approximately the same level with each subsequent treatment (green curve).
Figure 6
Figure 6
Baseline prevalence vs. Years until elimination: Here we vary β in the stochastic model, while keeping other parameters the same. Other parameters are biannual treatment with 90% effective coverage, an effective population size of 100 children, and γ = 0.017.
Figure 7
Figure 7
Recovery rate vs. Years until elimination: Here we vary the recovery rate in the stochastic model, while keeping other parameters the same. Other parameters are biannual treatment with 90% effective coverage, an effective population size of 100 children, and β = 0.044.
Figure 3
Figure 3
a. Probability Density of infection prevalence found in biannually treated villages where "village level" elimination has not yet occurred: Probability distribution of 1000 simulations at baseline, 6, 12, 18, and 24 months. The prevalence of infection in a simulated community pre-treatment varies in a normal distribution [21]. Each mass treatment eliminates infection in some villages, but in those that it does not, the distribution is shifted to the left, rapidly approaching a quasi-stationary distribution 3b. Probability density graphs using Ethiopian data: Distribution of the prevalence of infection in pre-school children in 16 Ethiopian villages. Baseline, 2, and 6 month data were used to fit the parameters of the stochastic model. Subsequent data from 12, 18, and 24 months confirm that the distribution of infection in the villages also approaches the quasi-stationary distribution.
Figure 2
Figure 2
a. Simulation data after one treatment: In identical simulated communities, infection responds to identical treatment in different ways. It may return after a single mass antibiotic treatment relatively rapidly (blue curve) or fade out (red curve) due to the effects of chance. b. Real Ethiopian villages after one treatment: In Ethiopian communities with similar pre-treatment prevalence of infection and similar antibiotic coverage levels, infection may return relatively rapidly (blue curve), or fade out (red curve).
Figure 4
Figure 4
Coverage vs. Years until elimination: Here we vary coverage in the stochastic model, while keeping other parameters the same. Other parameters are biannual treatment an effective population size of 100 children, γ = 0.017, and β = 0.044.
Figure 5
Figure 5
Number of months between treatments vs. Years until elimination: Here we vary treatment frequency in the stochastic model, while keeping other parameters the same. Other parameters are 90% effective coverage, an effective population size of 100 children, γ = 0.017, and β = 0.044.
Figure 8
Figure 8
Population vs. Years until elimination: Here we vary the effective population size of children in the stochastic model, while keeping other parameters the same. Other parameters are biannual treatment with 90% effective coverage, γ = 0.017, and β = 0.044.

References

    1. Thylefors B, Négrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull World Health Organ. 1995;73:115–121.
    1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–851.
    1. Report of the Eighth meeting of the W.H.O. Alliance for the Global Elimination of Blinding Trachoma. Geneva. 2004.
    1. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet. 1993;342:453–456. doi: 10.1016/0140-6736(93)91591-9.
    1. Dawson CR, Schachter J, Sallam S, Sheta A, Rubinstein RA, Washton H. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis. 1997;24:363–368.
    1. Schachter J, West SK, Mabey D, Dawson CR, Bobo L, Bailey R, Vitale S, Quinn TC, Sheta A, Sallam S, Mkocha H, Faal H. Azithromycin in control of trachoma. Lancet. 1999;354:630–635. doi: 10.1016/S0140-6736(98)12387-5.
    1. Melese M, Chidambaram JD, Alemayehu W, Lee DC, Yi EH, Cevallos V, Zhou Z, Donnellan C, Saidel M, Whitcher JP, Gaynor BD, Lietman TM. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA. 2004;292:721–725. doi: 10.1001/jama.292.6.721.
    1. Gaynor BD, Miao Y, Cevallos V, Jha H, Chaudary JS, Bhatta R, Osaki-Holm S, Yi E, Schachter J, Whitcher JP, Lietman T. Eliminating trachoma in areas with limited disease. Emerg Infect Dis. 2003;9:596–598.
    1. Solomon AW, Holland MJ, Alexander ND, Massae PA, Aguirre A, Natividad-Sancho A, Molina S, Safari S, Shao JF, Courtright P, Peeling RW, West SK, Bailey RL, Foster A, Mabey DC. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med. 2004;351:1962–1971. doi: 10.1056/NEJMoa040979.
    1. Chidambaram JD, Melese M, Alemayehu W, Yi E, Prabriputaloong T, Lee DC, Cevallos V, Zhou Z, Whitcher JP, Gaynor BD, Lietman TM. Mass antibiotic treatment and community protection in trachoma control programs. Clin Infect Dis. 2004;39:e95–7. doi: 10.1086/424747.
    1. West ES, Munoz B, Mkocha H, Holland MJ, Aguirre A, Solomon AW, Bailey R, Foster A, Mabey D, West SK. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci. 2005;46:83–87. doi: 10.1167/iovs.04-0327.
    1. Chidambaram JD, Lee DC, Porco TC, Lietman TM. Mass antibiotics for trachoma and the Allee effect. Lancet Infect Dis. 2005;5:194–196. doi: 10.1016/S1473-3099(05)70032-3.
    1. Burton MJ, Holland MJ, Makalo P, Aryee EA, Alexander ND, Sillah A, Faal H, West SK, Foster A, Johnson GJ, Mabey DC, Bailey RL. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet. 2005;365:1321–1328. doi: 10.1016/S0140-6736(05)61029-X.
    1. West SK, Munoz B, Mkocha H, Holland MJ, Aguirre A, Solomon AW, Foster A, Bailey RL, Mabey DC. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet. 2005;366:1296–1300. doi: 10.1016/S0140-6736(05)67529-0.
    1. Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, Cevallos V, Zhou Z, Maxey K, Shapiro B, Srinivasan M, Whitcher JP, Gaynor BD, Lietman TM. Return of Infectious Trachoma after a Single Mass Antibiotic Distribution. JAMA. 2006;295
    1. Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med. 1999;5:572–576. doi: 10.1038/8451.
    1. Diamont J, Moncada J, Pang F, Jha H, Benes R, Schachter J, Lietman. T. Pooling of Chlamydial Laboratory Tests to Determine Prevalence of Trachoma. Ophthalmic Epidemiology. 2001;8:109–117. doi: 10.1076/opep.8.2.109.4156.
    1. Hethcote HW, Yorke JA. Series Lecture notes in biomathematics. Vol. 56. Berlin , Springer-Verlag; 1984. Gonorrhea transmission dynamics and control.
    1. Lee DC, Chidambaram JD, Porco TC, Lietman TM. Seasonal effects in the elimination of trachoma. Am J Trop Med Hyg. 2005;72:468–470.
    1. Scott DW, Wand MP. Feasibility of Multivariate Density Estimates. Biometrika. 1991;78:197–205. doi: 10.1093/biomet/78.1.197.
    1. Nasell I. On the quasi-stationary distribution of the stochastic logistic epidemic. Mathematical Biosciences. 1999;156:21–40. doi: 10.1016/S0025-5564(98)10059-7.
    1. Jacquez JA, Simon CP. The stochastic SI model with recruitment and deaths. I. Comparison with the closed SIS model. Math Biosci. 1993;117:77–125. doi: 10.1016/0025-5564(93)90018-6.
    1. Nasell I. On the quasi-stationary distribution of the Ross malaria model. Mathematical Biosciences. 1991;107:187–207. doi: 10.1016/0025-5564(91)90004-3.
    1. Atik B, Thanh TT, Luong VQ, Lagree S, Dean D. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. Jama. 2006;296:1488–1497. doi: 10.1001/jama.296.12.1488.
    1. Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis. 2005;192:1836–1844. doi: 10.1086/497341.
    1. Yang JL., Lietman, T.L. The return of trachoma in partially treated communities. Archives of Ophthalmology. 2007;125:989–991. doi: 10.1001/archopht.125.7.989.
    1. Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, House J, Cevallos V, Zhou Z, Maxey K, Lee DC, Shapiro BL, Srinivasan M, Porco T, Whitcher JP, Gaynor BD, Lietman TM. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. Jama. 2006;295:1142–1146. doi: 10.1001/jama.295.10.1142.
    1. Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, Mathews JD. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis. 1997;24:356–362.
    1. Solomon AW, Mohammed Z, Massae PA, Shao JF, Foster A, Mabey DC, Peeling RW. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrob Agents Chemother. 2005;49:4804–4806. doi: 10.1128/AAC.49.11.4804-4806.2005.
    1. Fry AM, Jha HC, Lietman TM, Chaudhary JS, Bhatta RC, Elliott J, Hyde T, Schuchat A, Gaynor B, Dowell SF. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis. 2002;35:395–402. doi: 10.1086/341414.
    1. West S, Munoz B, Lynch M, Kayongoya A, Chilangwa Z, Mmbaga BB, Taylor HR. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet. 1995;345:155–158. doi: 10.1016/S0140-6736(95)90167-1.
    1. Emerson PM, Cairncross S, Bailey RL, Mabey DC. Review of the evidence base for the 'F' and 'E' components of the SAFE strategy for trachoma control. Trop Med Int Health. 2000;5:515–527. doi: 10.1046/j.1365-3156.2000.00603.x.
    1. Emerson PM, Lindsay SW, Alexander N, Bah M, Dibba SM, Faal HB, Lowe KO, McAdam KP, Ratcliffe AA, Walraven GE, Bailey RL. Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial. Lancet. 2004;363:1093–1098. doi: 10.1016/S0140-6736(04)15891-1.
    1. Miller K, Pakpour N, Yi E, Melese M, Alemayehu W, Bird M, Schmidt G, Cevallos V, Olinger L, Chidambaram J, Gaynor B, Whitcher J, Lietman T. Pesky trachoma suspect finally caught. The British journal of ophthalmology. 2004;88:750–751. doi: 10.1136/bjo.2003.038661.
    1. Chidambaram JD, Bird M, Schiedler V, Fry AM, Porco T, Bhatta RC, Jha H, Chaudary JSP, Gaynor B, Yi E, Whitcher JP, Osaki-Holm S, Lietman TM. Trachoma Decline and Widespread Use of Antimicrobial Drugs. Emerg Infect Dis. 2004;10:1895–1899.
    1. Dolin PJ, Faal H, Johnson GJ, Minassian D, Sowa S, Day S, Ajewole J, Mohamed AA, Foster A. Reduction of trachoma in a sub-Saharan village in absence of a disease control programme. Lancet. 1997;349:1511–1512. doi: 10.1016/S0140-6736(97)01355-X.
    1. Hoechsmann A, Metcalfe N, Kanjaloti S, Godia H, Mtambo O, Chiopeta T, Barrows J, Witte C, Courtright P. Reduction of trachoma in the absence of antibiotic treatment: Evidence from a population-based survey in Malawi. Ophthalmic Epidemiology. 2001;8:145–153. doi: 10.1076/opep.8.2.145.4169.
    1. Jha H, Chaudary JSP, Bhatta R, Miao Y, Osaki-Holm S, Gaynor B, Zegans M, Bird M, Yi E, Holbrook K, Whitcher JP, Lietman. T. Disappearance of trachoma in western Nepal. Clinical Infectious Diseases. 2002;35:765–768. doi: 10.1086/342298.

Source: PubMed

Подписаться